• 1
    Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. J. Pain Symptom Manage. 1994; 9: 372382.
  • 2
    Massie MJ. Prevalence of depression in patients with cancer. J. Natl Cancer Inst. Monogr. 2004; 32: 5771.
  • 3
    Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin. Cornerstone 2004; 6 (Suppl.): 1521.
  • 4
    Lee K, Cho M, Miaskowski C, Dodd M. Impaired sleep and rhythms in persons with cancer. Sleep Med. Rev. 2004; 8: 199212.
  • 5
    Andrews JM, Nemeroff CB. Contemporary management of depression. Am. J. Med. 1994; 97 (Suppl.): 2432.
  • 6
    Pinder RM. The pharmacology of mirtazapine. J. Clin. Psychiatry 1997; 58: 501502.
  • 7
    Guclu S, Gol M, Dogan E, Saygili U. Mirtazapine use in resistant hyperemesis gravidarum: Report of three cases and review of the literature. Arch. Gynecol. Obstet. 2005; 272: 298300.
  • 8
    Teixeira FV, Novaretti TM, Pilon B, Pereira PG, Breda MF. Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes. Surg. 2005; 15: 707709.
  • 9
    Kim SW, Shin IS, Kim JM et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006; 47: 440442.
  • 10
    Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 11431145.
  • 11
    Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study. Biol. Psychiatry 2000; 48: 7578.
  • 12
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). American Psychiatric Press, Washington, DC, 1994.
  • 13
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979; 134: 382389.
  • 14
    Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med. Care 1992; 30: 473483.
  • 15
    Kind P. The EuroQoL Instrument: An index of HRQOL. In : SpilkerB (ed.). Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Lippincott-Raven, Philadelphia, 1996; 191201.
  • 16
    Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta. Psychiatr. Scand. Suppl. 1987; 334: 1100.
  • 17
    Trovato JA, Stull DM, Finley RS. Outcomes of antiemetic therapy after the administration of high-dose antineoplastic agents. Am. J. Health Syst. Pharm. 1998; 55: 12691274.
  • 18
    Parrot AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigation: A review. Psychopharmacology 1980; 71: 173179.
  • 19
    Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with advanced cancer: Olanzapine and mirtazapine. A World Health Organization project. Expert Rev. Anticancer. Ther. 2002; 2: 365376.
  • 20
    Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41: 356359.
  • 21
    Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J. Pain Symptom Manage. 2002; 23: 442447.
  • 22
    Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support. Care Cancer 2001; 9: 469470.
  • 23
    Davidson JR, MacLean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. Soc. Sci. Med. 2002; 54: 13091321.
  • 24
    Radhakishun FS, Van Den Bos J, Van Der Heijden BC, Roes KC, O'Hanlon JF. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J. Clin. Psychopharmacol. 2000; 20: 531537.
  • 25
    Van Gool AR, Bannink M, Stronks DL, Vos MS. Re: Mirtazapine in cancer patients. J. Pain Symptom Manage. 2003; 25: 78.
  • 26
    Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: A meta-analysis of 39 placebo-controlled studies. Pain 1992; 49: 205219.
  • 27
    Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62: 17061711.
  • 28
    Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004; 37: 168170.
  • 29
    Freynhagen R, Muth-Selbach U, Lipfert P et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr. Med. Res. Opin. 2006; 22: 257264.
  • 30
    Wilson KG, Eriksson MY, D'Eon JL, Mikail SF, Emery PC. Major depression and insomnia in chronic pain. Clin. J. Pain 2002; 18: 7783.
  • 31
    Aukst-Margetic B, Jakovljevic M, Margetic B, Biscan M, Samija M. Religiosity, depression and pain in patients with breast cancer. Gen. Hosp. Psychiatry 2005; 27: 250255.
  • 32
    Massie MJ, Holland JC. The cancer patient with pain: Psychiatric complications and their management. J. Pain Symptom Manage. 1992; 7: 99109.
  • 33
    Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J. Clin. Pharmacol. 2004; 44: 10831105.
  • 34
    Yoon SJ, Pae CU, Kim DJ et al. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 11961201.